Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients.
Seree-Aphinan C, Ratanapokasatit Y, Suchonwanit P, Rattanakaemakorn P, O-Charoen P, Pisitkun P, Suangtamai T, Setthaudom C, Chirasuthat S, Chanprapaph K. Seree-Aphinan C, et al. Among authors: setthaudom c. Front Immunol. 2023 Mar 15;14:1138765. doi: 10.3389/fimmu.2023.1138765. eCollection 2023. Front Immunol. 2023. PMID: 37006291 Free PMC article.
Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants.
Seree-Aphinan C, Chanprapaph K, Rattanakaemakorn P, Setthaudom C, Suangtamai T, Pomsoong C, Ratanapokasatit Y, Suchonwanit P. Seree-Aphinan C, et al. Among authors: setthaudom c. Front Med (Lausanne). 2021 Dec 8;8:769845. doi: 10.3389/fmed.2021.769845. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34957149 Free PMC article.
A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.
Chanprapaph K, Seree-Aphinan C, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, Thitithanyanont A, Suriyo A, Suangtamai T, Suchonwanit P; COVIDVAC-DERM study group. Chanprapaph K, et al. Among authors: setthaudom c. Br J Dermatol. 2023 Feb 10;188(2):268-277. doi: 10.1093/bjd/ljac045. Br J Dermatol. 2023. PMID: 36637102
Risk-benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study.
Seree-Aphinan C, Suchonwanit P, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, Suangtamai T, Chanprapaph K; COVIDVAC-DERM study group. Seree-Aphinan C, et al. Among authors: setthaudom c. J Eur Acad Dermatol Venereol. 2023 May;37(5):e572-e575. doi: 10.1111/jdv.18890. Epub 2023 Jan 31. J Eur Acad Dermatol Venereol. 2023. PMID: 36662625 No abstract available.
SARS-CoV-2 neutralizing antibodies decline over one year and patients with severe COVID-19 pneumonia display a unique cytokine profile.
Vacharathit V, Srichatrapimuk S, Manopwisedjaroen S, Kirdlarp S, Srisaowakarn C, Setthaudom C, Inrueangsri N, Pisitkun P, Kunakorn M, Hongeng S, Sungkanuparph S, Thitithanyanont A. Vacharathit V, et al. Among authors: setthaudom c. Int J Infect Dis. 2021 Nov;112:227-234. doi: 10.1016/j.ijid.2021.09.021. Epub 2021 Sep 15. Int J Infect Dis. 2021. PMID: 34536610 Free PMC article.
The expansion of activated naive DNA autoreactive B cells and its association with disease activity in systemic lupus erythematosus patients.
Wangriatisak K, Thanadetsuntorn C, Krittayapoositpot T, Leepiyasakulchai C, Suangtamai T, Ngamjanyaporn P, Khowawisetsut L, Khaenam P, Setthaudom C, Pisitkun P, Chootong P. Wangriatisak K, et al. Among authors: setthaudom c. Arthritis Res Ther. 2021 Jul 6;23(1):179. doi: 10.1186/s13075-021-02557-0. Arthritis Res Ther. 2021. PMID: 34229724 Free PMC article.
A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants.
Bruminhent J, Autto S, Rotjanapan P, Ngarmjanyaporn P, Bushyakanist A, Kirdlarp S, O-Charoen P, Setthaudom C, Pisitkun P. Bruminhent J, et al. Among authors: setthaudom c. Open Forum Infect Dis. 2021 May 16;8(6):ofab248. doi: 10.1093/ofid/ofab248. eCollection 2021 Jun. Open Forum Infect Dis. 2021. PMID: 34189173 Free PMC article.
Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients.
Bruminhent J, Setthaudom C, Kitpermkiat R, Kiertiburanakul S, Malathum K, Assanatham M, Nongnuch A, Phuphuakrat A, Chaumdee P, Janphram C, Thotsiri S, Chuengsaman P, Boongird S. Bruminhent J, et al. Among authors: setthaudom c. Sci Rep. 2022 Mar 4;12(1):3587. doi: 10.1038/s41598-022-07574-w. Sci Rep. 2022. PMID: 35246578 Free PMC article.
SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study).
Bruminhent J, Setthaudom C, Chaumdee P, Boongird S, Kiertiburanakul S, Malathum K, Nongnuch A, Phuphuakrat A, Jirasiritham S, Janphram C, Thotsiri S, Upama S, Assanatham M; Ramathibodi Transplant Infectious Diseases (RTID) Study Group. Bruminhent J, et al. Among authors: setthaudom c. Am J Transplant. 2022 Mar;22(3):813-822. doi: 10.1111/ajt.16867. Epub 2021 Dec 6. Am J Transplant. 2022. PMID: 34657386 Free PMC article.
23 results